Increased Intestinal Permeability in Relatives of Patients With Crohn’s Disease Is Not Associated With Small Bowel Ulcerations
Christopher Teshima(University of Alberta), Levinus A. Dieleman(University of North Carolina at Chapel Hill), Rosica Valcheva(University of Alberta), Karen J. Goodman(University of Alberta), Samina A. Turk(University of Alberta), Marilyn Gordon(University of Calgary), Ronda G. Danchak(University of Alberta), Dina Kao(University of Alberta), Daniel J. Wong(University of Alberta), Peter Ho(Epizyme (United States)), Hien Q. Huynh(University of Alberta), Jonathan B. Meddings(University of Calgary), Amanda Mullins(University of Alberta), Mohamed El‐Kalla(University of Alberta), Wael El‐Matary(Children's Hospital Research Institute of Manitoba)
Cited by 34
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Joint ESPGHAN/NASPGHAN Guidelines for the Management of <i>Helicobacter pylori</i> in Children and Adolescents (Update 2016)
|Journal of Pediatric Gastroenterology and Nutrition|2017|467
Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease
|Gastroenterology|2020|308
Interleukin-1β and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Gastric Cancer: A Meta-analysis
|Cancer Epidemiology Biomarkers & Prevention|2006|237